IDH1 and glioblastoma: This analysis corroborated the finding that PDGFRA gain/amplification and unmethylated MGMTp were independent prognostic markers of OS in patients with IDH wild-type GBM [HR: 1.82 (1.00-3.31), P = .049; and HR: 3.00 (1.67-5.39), P < .001, respectively; Table 2].